Mycophenolate Case Study

839 Words4 Pages
The Metabolic fate of ethyl O-[N-(p-carboxyphenyl)-carbamoyl] mycophenolate (CAM), a new anticancer agent, in experimental animals. The pharmacokinetics of a new anti-tumor agent i.e. ethyl o- [N-(p- carboxy phenyl)- carbamoyl] Mycophenolate (CAM) was studied in mice by using 14 c-labeled CAM and also metabolic differences were studied in species like rats, mice, rabbits, guinea pigs & dogs. The absorption of CAM was rapid from the gastrointestinal tract of the animals, mice compared to other animals. Due to the concentration of radioactivity two peaks are observed in the plasma of mice which reflects the concentration of metabolites in the enterohepatic circulation. After doing the first peak was observed after 30 min. & the second one was observed after 6 hrs. In the bile the concentration of radioactivity was observed about 100…show more content…
The cellcept® IV solution was characterized by invitro in order to determine the benefits of the suspension of Mycophenolate mofetil over its solution form. The results have shown that aerosolization performance of both formulations were excellent. 24 hour single dose, pharmacokinetic studies followed by the inhalation both formulations and oral cellcept® administration were performed in rats. Mycophenolate mofetil was rapidly and completely metabolized into the active metabolite by oral drug administration where as partial and slow metabolism was observed by pulmonary drug administration. Hence the results have shown that inhaled Mycophenolate mofetil suspension form was displayed well favourable pharmacokinetic data than that of inhaled cellcept® IV solution

More about Mycophenolate Case Study

Open Document